• Responsible for arrangement of biophysics group with both internal and external biophysics capabilities.• Establishment and coordination of CRO efforts worldwide to expand internal bandwidth in both biophysics and protein sciences. Organizations collaborated with include: NovAlix, Wuxi, Biortus, Viva Biotech, Enzymlogic, Pelago, Selvita, and Biognosys. • Enabling orthogonal biophysical validation and discovery efforts for novel fungal metabolite-target pairs; provide critical positive and negative confirmation to enable or terminate programs as needed.

• Development of internal platform to observe induced-proximity therapeutics.• Mentorship of junior scientists.

• Biophysical investigation of molecular interactions in disease pathogenesis and early hit-finding. Extensive use of novel and established high-throughput biophysical methods (SPR, SEC-ASMS, Native-Mass Spec, Fluorescence, Thermal Shift, Microscale Thermophoresis) • Coordination of international CRO efforts to expand internal bandwidth and develop internal expertise using a variety of techniques. Organizations collaborated with include: NovAlix, Wuxi, Biortus, Evotec, Admera, Specs, Exscientia, Lexogen, BioSpring, Viva Biotech, Enzymlogic, Acrobiosystems, Griffith University, Axcelead, Pelago, Selvita, Charles River, and others. • Responsible for setting up internal and external RNA biophysics efforts.• Assisted in developing methods for PROTAC discovery efforts.• Aided internal education development at Takdea; created the first (now ongoing) intern research presentation conference at Takeda California, and the first virtual session during the COVID-19 pandemic.

• Investigation of immunology and disease pathogenesis using novel and established high-throughput assay methods. • Evaluated the molecular basis of Crohn’s disease (gut microbiome carbohydrate motifs), analysis of therapeutic compounds for Cystic Fibrosis (coordinated structural, binding, and functional receptor studies), screening of synthesized parasite (Leishmania) mono- and polymeric carbohydrate antigens, screening of HIV therapeutic small molecules and localized surface plasmon resonance (LSPR) studies for single molecule measurements.• De novo automation and refinement of novel analytical techniques (BSI), creation of new analytical methods involving nanoplasmonic signal enhancement and label-free protein detection in whole-cell systems. • Responsible for managing both internal and external collaborations as well as budgeting and timelines for milestones. • Mentoring and supervision of direct reports/students as well as colleagues.

• Establishing a program to investigate novel applications of label-free assay technology, primarily focused on integration of BSI with established assay methods. • Responsible for setup of new laboratory infrastructure as well as mentoring/supervision of undergraduate researchers.• Implemented a program of instruction in optical methods and microscopy for the Finn Lab, taught as an informal, graduate level course.

• Development of HTS membrane-based assay systems.• Key in successfully transferring a membrane-based HTS assay from a technical academic lab to an external business partner.• Responsible for troubleshooting, evaluating and developing milestones, and creation of documentation as well as budget allocation for start-up experiments.

• Application of lipid bilayer membrane technology to biochemical and instrumental systems.• Integration of label-free detection methods with novel protein nanoparticle systems.

• External development of label-free molecular detection technology (BSI).

• Conducted independent research in membrane and colloid physics and physical chemistry.• Responsible for all IT-related tasks within parent research laboratory